Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Net Cash Flow (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Net Cash Flow for 15 consecutive years, with -$2.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 998.28% to -$2.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.6 million, a 1007.83% increase, with the full-year FY2025 number at $10.9 million, up 467.44% from a year prior.
  • Net Cash Flow was -$2.6 million for Q4 2025 at Aytu Biopharma, down from $1.7 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $12.8 million in Q2 2025 to a low of -$9.3 million in Q3 2021.
  • A 5-year average of -$880473.7 and a median of -$328000.0 in 2023 define the central range for Net Cash Flow.
  • Biggest YoY gain for Net Cash Flow was 5094.72% in 2025; the steepest drop was 1063.2% in 2025.
  • Aytu Biopharma's Net Cash Flow stood at -$5.3 million in 2021, then grew by 17.51% to -$4.4 million in 2022, then skyrocketed by 90.02% to -$435000.0 in 2023, then surged by 166.67% to $290000.0 in 2024, then tumbled by 998.28% to -$2.6 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Net Cash Flow are -$2.6 million (Q4 2025), $1.7 million (Q3 2025), and $12.8 million (Q2 2025).